Supplementary Table 4. Influence of immune infiltrated and stroma markers on recurrence-free survival in different lymphatic metastatic status (n=359)

Characteristics	Stratification	Lymph node positive			Lymph node negative		
		mRFS (95% CI)	χ^2	P-value	mRFS (95% CI)	χ^2	P-value
CD3	Low	8.20 (5.30–9.10)	2.91	0.880	9.60 (7.10–15.40)	12.46	<0.001
	High	8.50 (2.50–18.40)			21.40 (17.10–36.10)		
CD4	Low	8.60 (6.20–10.90)	0.51	0.470	11.80 (8.10–17.30)	13.16	<0.001
	High	6.80 (2.50–11.70)			26.20 (15.70–45.90)		
CD8	Low	8.55 (6.40–10.90)	0.37	0.541	11.70 (8.00–16.90)	18.35	<0.001
	High	5.90 (2.50–11.70)			29.90 (16.30–49.40)		
Foxp3	Low	7.60 (5.30–9.70)	0.16	0.693	18.40 (12.70–24.10)	2.23	0.136
	High	8.55 (2.10–11.70)			11.80 (8.40–20.20)		
CD68	Low	8.60 (4.90–10.90)	0.2	0.657	20.20 (15.40–29.90)	4.32	0.038
	High	7.45 (2.50–11.30)			10.60 (8.60–17.30)		
CD66b	Low	8.60 (6.70–11.30)	12.59	<0.001	19.40 (14.50–25.90)	10.05	0.002
	High	2.30 (0.20–5.90)			6.85 (5.70–15.40)		
Stroma	Dormant	7.15 (0.10–26.10)	0.82	0.844	46.20 (17.80~)	18.4	<0.001
	Fibrogenic	8.45 (2.40–12.00)			15.50 (10.50–24.10)		
	Inert	7.25 (1.60–11.70)			17.30 (10.20–26.20)		
	Fibrolytic	8.50 (2.40–12.00)			8.50 (6.60–11.70)		

CI, confidence interval; mRFS, median recurrence free survival.